Report

Update: Data and new trials in H214

BioLineRx should report partial data on BL-8040 in acute myeloid leukaemia (AML) and start a new clinical trial with the product in Q314. Upcoming Phase I/II data on BL-7010 for celiac disease should clear the way for its development as a medical device, with a pivotal trial beginning in early 2015. The trial with BL-1040 for patients after an acute myocardial infarction (AMI) has recruited over 200 patients, albeit slower than hoped; completion of this pivotal study is now due in mid-2015.
Underlying
BioLine Rx Ltd

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch